BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther. 2002;72:524-535. [PMID: 12426516 DOI: 10.1067/mcp.2002.128387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First-Pass CYP3A Activity. The Journal of Clinical Pharmacology 2005;45:1187-97. [DOI: 10.1177/0091270005280077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
2 Kirwan C, MacPhee I, Philips B. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? Expert Opin Drug Metab Toxicol 2010;6:761-71. [PMID: 20402562 DOI: 10.1517/17425255.2010.482929] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Chen Y, Zhang W, Huang W, Tan Z, Wang Y, Huang X, Zhou H. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:1933-8. [DOI: 10.1007/s00228-013-1554-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
4 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
5 Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation. Drug Metab Dispos 2007;36:146-54. [DOI: 10.1124/dmd.107.018382] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
6 Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004;57:600-10. [PMID: 15089813 DOI: 10.1111/j.1365-2125.2003.02053.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
7 Laille E, Patel M, Jones SF, Burris HA 3rd, Infante J, Lemech C, Liu L, Arkenau HT. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer. J Clin Pharmacol 2015;55:1378-85. [PMID: 26053962 DOI: 10.1002/jcph.560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011;89:693-701. [PMID: 21451505 DOI: 10.1038/clpt.2011.25] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
9 de Wildt SN, Berns MJ, van den Anker JN. 13C-Erythromycin Breath Test as a Noninvasive Measure of CYP3A Activity in Newborn Infants: A Pilot Study. Therapeutic Drug Monitoring 2007;29:225-30. [DOI: 10.1097/ftd.0b013e31803d156d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
10 de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today 2009;14:6-15. [PMID: 18721895 DOI: 10.1016/j.drudis.2008.07.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
11 Ahsman MJ, Tibboel D, Mathot RA, de Wildt SN. Sample collection, biobanking, and analysis. Handb Exp Pharmacol 2011;205:203-17. [PMID: 21882113 DOI: 10.1007/978-3-642-20195-0_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL, Martínez E, Gatell JM. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007;8:131-4. [PMID: 17352770 DOI: 10.1111/j.1468-1293.2007.00442.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
13 Yamazaki S, Johnson TR, Smith BJ. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. Drug Metab Dispos. 2015;43:1417-1429. [PMID: 26180127 DOI: 10.1124/dmd.115.064618] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
14 Ogasawara A, Kume T, Kazama E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 2007;35:410-8. [PMID: 17142564 DOI: 10.1124/dmd.106.011288] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kharasch ED, Walker A, Hoffer C, Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol 2005;45:79-88. [PMID: 15601808 DOI: 10.1177/0091270004269705] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
16 Vourvahis M, Kashuba ADM. Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir-Enhanced Tipranavir. Pharmacotherapy 2007;27:888-909. [DOI: 10.1592/phco.27.6.888] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
17 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
18 Devane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers. Journal of Clinical Psychopharmacology 2004;24:4-10. [DOI: 10.1097/01.jcp.0000104908.75206.26] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
19 Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005;5:207-17. [PMID: 15643980 DOI: 10.1111/j.1600-6143.2005.00748.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
20 Shon JH, Yeo CW, Liu KH, Lee SS, Cha IJ, Shin JG. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J Clin Pharmacol 2010;50:195-204. [PMID: 19841159 DOI: 10.1177/0091270009348974] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30:e13302. [PMID: 29441683 DOI: 10.1111/nmo.13302] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
22 Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008;335:126-36. [PMID: 18277121 DOI: 10.1097/MAJ.0b013e31814a586a] [Cited by in Crossref: 87] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
23 Lemahieu WPD, Maes BD, Ghoos Y, Rutgeerts P, Verbeke K, Vanrenterghem Y. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [ 14 C]erythromycin breath and urine test. American Journal of Physiology-Gastrointestinal and Liver Physiology 2003;285:G470-82. [DOI: 10.1152/ajpgi.00028.2003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
24 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Boston: Springer US; 2005. pp. 377-530. [DOI: 10.1007/0-387-27447-2_10] [Cited by in Crossref: 176] [Cited by in F6Publishing: 95] [Reference Citation Analysis]
25 Guengerich F. Cytochrome P450 Enzymes. Comprehensive Toxicology. Elsevier; 2018. pp. 54-86. [DOI: 10.1016/b978-0-12-801238-3.01960-7] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Guengerich F. Cytochrome P450 Enzymes. Comprehensive Toxicology. Elsevier; 2010. pp. 41-76. [DOI: 10.1016/b978-0-08-046884-6.00404-8] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and Low‐Dose Ritonavir in HIV‐Infected Patients. CLIN INFECT DIS 2004;38:426-9. [DOI: 10.1086/380794] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
28 Shroads AL, Langaee T, Coats BS, Kurtz TL, Bullock JR, Weithorn D, Gong Y, Wagner DA, Ostrov DA, Johnson JA, Stacpoole PW. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol 2012;52:837-49. [PMID: 21642471 DOI: 10.1177/0091270011405664] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
29 Nicandro JPA, Tsourounis C, Frassetto L, Guglielmo BJ. In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4. Journal of Herbal Pharmacotherapy 2009;7:39-56. [DOI: 10.1080/j157v07n01_04] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
30 McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 2011;118:326-34. [PMID: 21596492 DOI: 10.1016/j.drugalcdep.2011.04.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
31 Beringer PM, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother. 2005;39:1097-1108. [PMID: 15886292 DOI: 10.1345/aph.1e614] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
32 Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide. Clin Transl Sci 2017;10:271-9. [PMID: 28371445 DOI: 10.1111/cts.12458] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
33 Sugiyama E, Kikuchi A, Inada M, Sato H. The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats. J Pharm Sci 2011;100:3995-4005. [PMID: 21618542 DOI: 10.1002/jps.22616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]